Allergy Therapeutics plc (LON:AGY) insider Nicolas Wykeman bought 150,000 shares of Allergy Therapeutics plc stock in a transaction on Tuesday, September 27th. The shares were acquired at an average cost of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44).
Shares of Allergy Therapeutics plc (LON:AGY) opened at 20.00 on Friday. The company’s market capitalization is GBX 111.90 million. The stock has a 50 day moving average of GBX 18.72 and a 200-day moving average of GBX 22.42. Allergy Therapeutics plc has a 1-year low of GBX 17.25 and a 1-year high of GBX 34.82.
A number of equities research analysts have weighed in on the stock. Panmure Gordon reissued a “buy” rating and set a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Friday, June 10th. Stifel Nicolaus reissued a “buy” rating and set a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Finally, Numis Securities Ltd began coverage on shares of Allergy Therapeutics plc in a report on Wednesday, September 21st. They set a “buy” rating and a GBX 37 ($0.48) target price on the stock.
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.